Skip to main content

Study of 3-Day Partial Breast Radiation Therapy for the Treatment of Stage I Breast Cancer

Trial Status: Active

This phase II trial studies the side effects of a short-course (3-day) schedule of partial breast radiation therapy in treating patients with stage I breast cancer. Partial breast irradiation prevents cancer from growing back after a lumpectomy procedure while limiting radiation exposure to only those areas of the breast where radiation is needed, which may cause fewer and less severe side effects. The 3-day study treatment schedule is shorter than the usual 10-day schedule but it delivers the same total dose of radiation, and it may provide the same benefits of the usual schedule.

Inclusion Criteria

  • Unicentric pathological stage I (pT1 or T2 pN0-M0) invasive ductal breast cancer or ductal carcinoma in situ (DCIS) measuring < 3 cm in longest diameter on pathology and/or mammogram that is histologically confirmed. If T2, the tumor must be less than 3cm in longest diameter. Note: Women >= 70 years or older with T1 invasive ductal carcinoma who are estrogen- receptor positive (ER+) with clinically negative axillary nodes, and do not undergo surgical lymph node evaluation are eligible. Patients with T1N0(i+) tumors on sentinel lymph node mapping or dissection (i.e., if tumor deposit is 0.2 mm or less, regardless of whether the deposit is detected by immunohistochemistry or hematoxylin and eosin staining) will also be eligible
  • Histologically negative tumor margin or no tumor in a re-excision specimen on final shaved specimen
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Clips must be placed in the lumpectomy cavity at the time of final excision in order to aid in the delineation of the tumor cavity at the time of simulation and radiation delivery
  • Negative serum pregnancy test within 14 days prior to study treatment if a woman has child-bearing potential. Subjects of child bearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
  • Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the duration of study participation. Should a woman become pregnant while participating on study, she should inform the treating physician immediately
  • INTERMEDIATE RISK SUBSTUDY: * Post-NAC cohort patients: clinical T1 or T2 (less than or equal to 5 cm in longest diameter on available imaging) and clinical N0 (on exam and imaging) with pathological pT0 or pTis and pN0 (any regimen of neoadjuvant chemotherapy agents is allowed) OR * Oncotype RS score of 26 or higher OR * PAM50 ROR scored as “HIGH” OR * Presence of LVI (focal, limited or “not otherwise specified”) in the lumpectomy specimen OR * Age 40-49 years (ALL OF THE FOLLOWING MUST BE TRUE : 1) no history of prior benign breast biopsies, 2) no concomitant or prior atypia in either breast, 3) no concomitant or prior lobular breast carcinoma in situ (LCIS) in either breast, 4) no family history of breast cancer in first degree relatives) OR * Invasive lobular carcinoma OR * Women 70 or older w ith tumors 2.0 cm or less in size and w ith clinically or pathologically negative nodes w ho decline or are ineligible for hormonal therapy OR discontinue hormonal therapy within 3 months of initiating treatment

Exclusion Criteria

  • Patients with distant metastasis
  • Patients who are pregnant or breastfeeding
  • Patients with diffuse (> 1 quadrant or > 5 cm) suspicious microcalcifications or patients with known multicentric OR multifocal disease (microscopic multifocal disease that may be unifocal and/or appear multifocal due to sectioning is allowed after review with principal investigator [PI])
  • Prior radiation therapy to the ipsilateral or contralateral breast or thorax
  • Histological evidence of extensive lymphovascular invasion (LVI)
  • Histologic evidence of extensive intraductal component (EIC), defined as the presence of intraductal carcinoma both within the primary infiltrating ductal tumor (comprising at least 25% of the tumor area) and intraductal carcinoma present clearly beyond the edges of the invasive tumor
  • Patients are not required to undergo BRCA1 and BRCA2 or other genetic mutation tests in order to enroll on the study. Note: In the event a patient is tested and is found to be a mutation carrier, she would be excluded from the study. It would be an extremely rare/unlikely scenario for patients to be discovered BRCA positive after the completion of PBI, as all patients with risk factors for BRCA mutations (positive family history, Ashkenazi Jewish descent, ER-/PR-/her2-neu negative receptor status) are usually tested prior to radiation. Should such a situation exist, these patients will be given the option of remaining on the breast conservation paradigm or opting for mastectomy (as is done in this rare scenario is standard of care practice). The patient will be replaced on the trial
  • History of cosmetic or reconstructive breast surgery
  • Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have "currently active" malignancies if they have completed therapy and are considered by their physicians to be at < 5% risk of relapse within 3 years
  • Patients who are already enrolled in or planning to enroll in other adjuvant systemic therapy protocols for both non-invasive or invasive breast cancer
  • Expecting to conceive within the projected duration of the trial, starting with screening visit through 180 days after the last dose of trial treatment
  • Concomitant anti-neoplastic treatment is not allowed during protocol treatment and should be completed at least 2 weeks prior to commencement of protocol treatment, with resolution of associated acute toxicities. Bisphosphonates are permitted without restriction even during protocol treatment. Note: This does not apply to hormonal therapies such as tamoxifen or aromatase inhibitors (AIs), which are permitted. This does not apply to anti-Her2 therapies such as trastuzumab or TDM-1, which are also permitted
  • Ongoing therapy with other investigational agents. Patients may not be receiving any other investigational agents


Norwalk Hospital
Status: ACTIVE
Contact: Philip Gilbo
Phone: 203-845-4811


Miami Cancer Institute
Status: ACTIVE
Contact: Rupesh Rajesh Kotecha
Phone: 786-596-2000

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: ACTIVE
Contact: Atif Jalees Khan
Phone: 848-225-6334
Memorial Sloan Kettering Monmouth
Status: ACTIVE
Contact: Atif Jalees Khan
Phone: 848-225-6334
Memorial Sloan Kettering Bergen
Status: ACTIVE
Contact: Atif Jalees Khan
Phone: 848-225-6334

New York

Memorial Sloan Kettering Commack
Status: ACTIVE
Contact: Atif Jalees Khan
Phone: 848-225-6334
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Atif Jalees Khan
Phone: 848-225-6334
Memorial Sloan Kettering Nassau
Status: ACTIVE
Contact: Atif Jalees Khan
Phone: 848-225-6334
West Harrison
Memorial Sloan Kettering Westchester
Status: ACTIVE
Contact: Atif Jalees Khan
Phone: 848-225-6334


I. To assess the serious toxicity rate at 2 years with this abbreviated course of accelerated partial breast irradiation (APBI) among 130 evaluable patients.

II. To evaluate the 3-year local recurrence risk in women in the intermediate risk cohort (defined as having at least one of the following the findings: complete responders after neoadjuvant chemotherapy [NAC], high-risk scores on expression analysis assays, presence of lymph-vascular invasion [LVI], young age defined as 40-49, and invasive lobular carcinoma).


I. To estimate the cumulative incidence of serious toxicity and the cumulative incidence of local recurrence in addition to the binary endpoints used for the primary analysis.

II. To descriptively characterize the toxicities of a short 3 fraction schedule of APBI.

III. To assess patient reported skin toxicity using Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) and to understand the time frame of maximum skin toxicity post-APBI.

IV. To assess physician and patient reported cosmesis, and patient reported satisfaction and quality of life with treatment using the Breast Cancer Treatment Outcomes Scale (BCTOS).


Patients undergo APBI via external beam radiation therapy techniques for 3 fractions over 3 consecutive weekdays.

After completion of study treatment, patients are followed up at 1-8 weeks, 12, 24, and 36 months.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Atif Jalees Khan

  • Primary ID 19-300
  • Secondary IDs NCI-2019-06378
  • ID NCT04084730